top of page
News
SENSY: Groundbreaking Technology for Diabetic Neuropathy
Neurotech Reports highlights Sensars as an emerging company with groundbreaking technology for the treatment of painful diabetic neuropathy. Read More >
.png)
Sensars gets funding of €1.4M to advance its SENSY product.
This includes a €350,000 investment from HTH and a €500,000 Eurostars grant for its SENSOLE project. Additionally, Sensars Germany received a €600,000 grant from BMBF to test the SENSY neurostimulator in amputees. Read More>
Sensars coordinates a €3 million grant to test its bionic prosthetics
Sensars has received a 3 million EUR grant as part of the European Union’s Horizon Research and Innovation program. The startup will coordinate and use the funds to further develop and test its product - the neuroprosthetic system. Read More >
Top '20 Most Innovative Companies to Watch, 2022
Sensars Named In Business Worldwide Magazines' Top '20 Most Innovative Companies to Watch, 2022. Read More >
Sensars receives FDA Breakthrough Device Designation
Two Swiss start-ups have been granted FDA Breakthrough Device Designation recently: AMF for its Sigi Insulin Management system and Sensars for its system providing sensory feedback for those with limb loss to improve prosthesis function. Read More >
bottom of page